94 related articles for article (PubMed ID: 34081080)
1. Assessing the Association of Targeted Therapy and Intracranial Metastatic Disease.
Erickson AW; Habbous S; Wright F; Lofters AK; Jerzak KJ; Das S
JAMA Oncol; 2021 Aug; 7(8):1220-1224. PubMed ID: 34081080
[TBL] [Abstract][Full Text] [Related]
2. Changes in Health Care Costs, Survival, and Time Toxicity in the Era of Immunotherapy and Targeted Systemic Therapy for Melanoma.
Bateni SB; Nguyen P; Eskander A; Seung SJ; Mittmann N; Jalink M; Gupta A; Chan KKW; Look Hong NJ; Hanna TP
JAMA Dermatol; 2023 Nov; 159(11):1195-1204. PubMed ID: 37672282
[TBL] [Abstract][Full Text] [Related]
3. HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis.
Erickson AW; Ghodrati F; Habbous S; Jerzak KJ; Sahgal A; Ahluwalia MS; Das S
Neurooncol Adv; 2020; 2(1):vdaa136. PubMed ID: 33305268
[TBL] [Abstract][Full Text] [Related]
4. Incidence and real-world burden of brain metastases from solid tumors and hematologic malignancies in Ontario: a population-based study.
Habbous S; Forster K; Darling G; Jerzak K; Holloway CMB; Sahgal A; Das S
Neurooncol Adv; 2021; 3(1):vdaa178. PubMed ID: 33585818
[TBL] [Abstract][Full Text] [Related]
5. Metastatic Breast Cancer to the Spine: Incidence of Somatic Gene Alterations and Association of Targeted Therapies With Overall Survival.
Rabah NM; Jarmula J; Hamza O; Khan HA; Chakravarthy V; Habboub G; Wright JM; Steinmetz MP; Wright CH; Krishnaney AA
Neurosurgery; 2023 Jun; 92(6):1183-1191. PubMed ID: 36735514
[TBL] [Abstract][Full Text] [Related]
6. Association between Medicaid Expansion and Cutaneous Melanoma Diagnosis and Outcomes: Does Where You Live Make a Difference?
Greene AC; Ziegler O; Quattrone M; Stack MJ; Becker B; Pameijer CR; Shen C
Ann Surg Oncol; 2024 Mar; ():. PubMed ID: 38553653
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of genetic profiling based on different anatomic sites in patients with mucosal melanoma who received or did not receive immune checkpoint inhibitors.
Wang HY; Liu Y; Deng L; Jiang K; Yang XH; Wu XY; Guo KH; Wang F
Cancer Cell Int; 2023 Aug; 23(1):187. PubMed ID: 37649078
[TBL] [Abstract][Full Text] [Related]
8. Systemic therapy timing and use in patients with advanced melanoma at the end of life: A retrospective cohort study.
van Lith PEA; Schreuder K; Jalving M; Reyners AKL; Been LB; Rácz E; Fransen HP; Louwman MWJ
J Dermatol; 2024 Apr; 51(4):584-591. PubMed ID: 38078557
[TBL] [Abstract][Full Text] [Related]
9. Does the Primary Care Experience Influence the Cancer Diagnostic Process?
Provost S; Pineault R; Tousignant P; Roberge D; Tremblay D; Breton M; Benhadj L; Diop M; Fournier M; Brousselle A
Int J Family Med; 2015; 2015():176812. PubMed ID: 26504599
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Olaparib for Patients with
Tutt ANJ; Garber JE; Kaufman B; Viale G; Fumagalli D; Rastogi P; Gelber RD; de Azambuja E; Fielding A; Balmaña J; Domchek SM; Gelmon KA; Hollingsworth SJ; Korde LA; Linderholm B; Bandos H; Senkus E; Suga JM; Shao Z; Pippas AW; Nowecki Z; Huzarski T; Ganz PA; Lucas PC; Baker N; Loibl S; McConnell R; Piccart M; Schmutzler R; Steger GG; Costantino JP; Arahmani A; Wolmark N; McFadden E; Karantza V; Lakhani SR; Yothers G; Campbell C; Geyer CE;
N Engl J Med; 2021 Jun; 384(25):2394-2405. PubMed ID: 34081848
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial.
Jabbour SK; Lee KH; Frost N; Breder V; Kowalski DM; Pollock T; Levchenko E; Reguart N; Martinez-Marti A; Houghton B; Paoli JB; Safina S; Park K; Komiya T; Sanford A; Boolell V; Liu H; Samkari A; Keller SM; Reck M
JAMA Oncol; 2021 Jun; 7(9):1-9. PubMed ID: 34086039
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial.
Hatschek T; Foukakis T; Bjöhle J; Lekberg T; Fredholm H; Elinder E; Bosch A; Pekar G; Lindman H; Schiza A; Einbeigi Z; Adra J; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Agartz S; Azavedo E; Grybäck P; Hellström M; Johansson H; Maes C; Zerdes I; Hartman J; Brandberg Y; Bergh J
JAMA Oncol; 2021 Sep; 7(9):1360-1367. PubMed ID: 34165503
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial.
Guarneri V; Dieci MV; Griguolo G; Miglietta F; Girardi F; Bisagni G; Generali DG; Cagossi K; Sarti S; Frassoldati A; Gianni L; Cavanna L; Pinotti G; Musolino A; Piacentini F; Cinieri S; Prat A; Conte P;
Eur J Cancer; 2021 Aug; 153():133-141. PubMed ID: 34153715
[TBL] [Abstract][Full Text] [Related]
14. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
Gainor JF; Curigliano G; Kim DW; Lee DH; Besse B; Baik CS; Doebele RC; Cassier PA; Lopes G; Tan DSW; Garralda E; Paz-Ares LG; Cho BC; Gadgeel SM; Thomas M; Liu SV; Taylor MH; Mansfield AS; Zhu VW; Clifford C; Zhang H; Palmer M; Green J; Turner CD; Subbiah V
Lancet Oncol; 2021 Jul; 22(7):959-969. PubMed ID: 34118197
[TBL] [Abstract][Full Text] [Related]
15. Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib.
Brase JC; Walter RFH; Savchenko A; Gusenleitner D; Garrett J; Schimming T; Varaljai R; Castelletti D; Kim J; Dakappagari N; Schultz K; Robert C; Long GV; Nathan PD; Ribas A; Flaherty KT; Karaszewska B; Schachter J; Sucker A; Schmid KW; Zimmer L; Livingstone E; Gasal E; Schadendorf D; Roesch A
Clin Cancer Res; 2021 Aug; 27(16):4500-4510. PubMed ID: 34108180
[TBL] [Abstract][Full Text] [Related]
16. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.
Slamon DJ; Neven P; Chia S; Jerusalem G; De Laurentiis M; Im S; Petrakova K; Valeria Bianchi G; Martín M; Nusch A; Sonke GS; De la Cruz-Merino L; Beck JT; Ji Y; Wang C; Deore U; Chakravartty A; Zarate JP; Taran T; Fasching PA
Ann Oncol; 2021 Aug; 32(8):1015-1024. PubMed ID: 34102253
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases.
Huang RSP; Haberberger J; McGregor K; Mata DA; Decker B; Hiemenz MC; Lechpammer M; Danziger N; Schiavone K; Creeden J; Graf RP; Strowd R; Lesser GJ; Razis ED; Bartsch R; Giannoudis A; Bhogal T; Lin NU; Pusztai L; Ross JS; Palmieri C; Ramkissoon SH
Oncologist; 2021 Oct; 26(10):835-844. PubMed ID: 34105210
[TBL] [Abstract][Full Text] [Related]
18. Sotorasib for Lung Cancers with
Skoulidis F; Li BT; Dy GK; Price TJ; Falchook GS; Wolf J; Italiano A; Schuler M; Borghaei H; Barlesi F; Kato T; Curioni-Fontecedro A; Sacher A; Spira A; Ramalingam SS; Takahashi T; Besse B; Anderson A; Ang A; Tran Q; Mather O; Henary H; Ngarmchamnanrith G; Friberg G; Velcheti V; Govindan R
N Engl J Med; 2021 Jun; 384(25):2371-2381. PubMed ID: 34096690
[TBL] [Abstract][Full Text] [Related]
19. Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial.
Friedl TWP; Fehm T; Müller V; Lichtenegger W; Blohmer J; Lorenz R; Forstbauer H; Fink V; Bekes I; Huober J; Jückstock J; Schneeweiss A; Tesch H; Mahner S; Brucker SY; Heinrich G; Häberle L; Fasching PA; Beckmann MW; Coleman RE; Janni W; Rack B
JAMA Oncol; 2021 Aug; 7(8):1149-1157. PubMed ID: 34165508
[TBL] [Abstract][Full Text] [Related]
20. Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial.
Hui Z; Men Y; Hu C; Kang J; Sun X; Bi N; Zhou Z; Liang J; Lv J; Feng Q; Xiao Z; Chen D; Wang Y; Li J; Wang J; Gao S; Wang L; He J
JAMA Oncol; 2021 Aug; 7(8):1178-1185. PubMed ID: 34165501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
